-
Subject Areas on Research
-
17Beta-estradiol suppresses TLR3-induced cytokine and chemokine production in endometrial epithelial cells.
-
27-Hydroxycholesterol: a potential endogenous regulator of estrogen receptor signaling.
-
27-hydroxycholesterol is an endogenous selective estrogen receptor modulator.
-
A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.
-
A joint analysis of metabolomics and genetics of breast cancer.
-
A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer.
-
A machine learning approach to radiogenomics of breast cancer: a study of 922 subjects and 529 DCE-MRI features.
-
A negative coregulator for the human ER.
-
A novel human endometrial epithelial cell line for modeling gynecological diseases and for drug screening.
-
A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007.
-
A reevaluation of the concept of separable periods of organizational and activational actions of estrogens in development of brain and behavior.
-
A role for the androgen receptor in the treatment of male breast cancer.
-
A tamoxifen inducible knock-in allele for investigation of E2A function.
-
ASO Visual Abstract: Machine Learning-Based Epigenetic Classifiers for Axillary Staging of Patients with ER-Positive Early-Stage Breast Cancer.
-
Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
-
Absence of estrogen receptor in human melanoma as evaluated by a monoclonal antiestrogen receptor antibody.
-
Acquisition of metastatic tissue from patients with bone metastases from breast cancer.
-
Actions of steroids in mitochondria.
-
Additive estrogenic activities of a binary mixture of 2',4',6'-trichloro- and 2',3',4',5'-tetrachloro-4-biphenylol.
-
Adherence to Adjuvant Endocrine Therapy in Insured Black and White Breast Cancer Survivors: Exploring Adherence Measures in Patient Data.
-
Adjuvant chemotherapy in older women with early-stage breast cancer.
-
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer.
-
Ager-CreERT2: A New Genetic Tool for Studying Lung Alveolar Development, Homeostasis, and Repair.
-
Aggressive fibromatosis.
-
Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements.
-
Analysing breast cancer microarrays from African Americans using shrinkage-based discriminant analysis.
-
Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens.
-
Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion.
-
Analysis of the molecular pharmacology of estrogen receptor agonists and antagonists provides insights into the mechanism of action of estrogen in bone.
-
Antiestrogen can establish nonproductive receptor complexes and alter chromatin structure at target enhancers.
-
Application of random peptide phage display to the study of nuclear hormone receptors.
-
Are all aromatase inhibitors alike?
-
Association of Parity and Time since Last Birth with Breast Cancer Prognosis by Intrinsic Subtype.
-
Association of aspirin use and hormone receptor status with breast cancer risk.
-
Autoradiographic analysis of nuclear estrogen binding sites during postnatal development of the genital tract of female mice.
-
Axillary Nodal Evaluation in Elderly Breast Cancer Patients: Potential Effects on Treatment Decisions and Survival.
-
BRCA1 expression is not directly responsive to estrogen.
-
Bayesian analysis of binary prediction tree models for retrospectively sampled outcomes.
-
Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database.
-
Biological assessments of a mixture of endocrine disruptors at environmentally relevant concentrations in water following UV/H2O2 oxidation.
-
Bisphenol A interacts with the estrogen receptor alpha in a distinct manner from estradiol.
-
Body mass index is associated with gene methylation in estrogen receptor-positive breast tumors.
-
Borderline Estrogen Receptor-Positive Breast Cancers in Black and White Women.
-
Breast Cancer Biology: Clinical Implications for Breast Radiation Therapy.
-
Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms.
-
Breast cancer patients' treatment expectations after exposure to the decision aid program adjuvant online: the influence of numeracy.
-
Breast cancer survival in African-American women by hormone receptor subtypes.
-
Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score.
-
CAPER is vital for energy and redox homeostasis by integrating glucose-induced mitochondrial functions via ERR-α-Gabpa and stress-induced adaptive responses via NF-κB-cMYC.
-
CCDC62/ERAP75 functions as a coactivator to enhance estrogen receptor beta-mediated transactivation and target gene expression in prostate cancer cells.
-
CNS location of uterine-related neurons revealed by trans-synaptic tracing with pseudorabies virus and their relation to estrogen receptor-immunoreactive neurons.
-
Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer.
-
Capitalizing on the complexities of estrogen receptor pharmacology in the quest for the perfect SERM.
-
Carbamate derivatives of colchicine show potent activity towards primary acute lymphoblastic leukemia and primary breast cancer cells-in vitro and ex vivo study.
-
Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.
-
Cellular mechanisms which distinguish between hormone- and antihormone-activated estrogen receptor.
-
Chemoprevention of NMU-induced rat mammary carcinoma with the combination of melatonin and 9-cis-retinoic acid.
-
Cholesterol and breast cancer pathophysiology.
-
Circulating vitamin D concentrations and risk of breast and prostate cancer: a Mendelian randomization study.
-
Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor.
-
Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer.
-
Clinical Impact of 21-Gene Recurrence Score Test Within the Veterans Health Administration: Utilization and Receipt of Guideline-Concordant Care.
-
Clinical application of array-based comparative genomic hybridization to define the relationship between multiple synchronous tumors.
-
Clinical response to hormone therapy correlated with estrogen receptor analyses. Biochemical v histochemical methods.
-
Coactivator AIB1 links estrogen receptor transcriptional activity and stability.
-
Combined effects of dietary phytoestrogen and synthetic endocrine-active compound on reproductive development in Sprague-Dawley rats: genistein and methoxychlor.
-
Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein.
-
Common genetic determinants of breast-cancer risk in East Asian women: a collaborative study of 23 637 breast cancer cases and 25 579 controls.
-
Comparative analyses of mechanistic differences among antiestrogens.
-
Comprehensive molecular portraits of human breast tumours.
-
Computational approach to radiogenomics of breast cancer: Luminal A and luminal B molecular subtypes are associated with imaging features on routine breast MRI extracted using computer vision algorithms.
-
Connections and regulation of the human estrogen receptor.
-
Creatine kinase activity as an indicator of unopposed estrogen action in the mouse uterus associated with anti-progesterone treatment.
-
Creation of an active estrogen-responsive element by a single base change in the flanking sequence of a cellular oncogene: a possible mechanism for hormonal carcinogenesis?
-
Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer.
-
Cystosarcoma phylloides. A steroid receptor and ultrastructure analysis.
-
Cytochemistry of sex steroid receptors: a critique.
-
Death-associated protein kinase 1 promotes growth of p53-mutant cancers.
-
Definition of the cellular mechanisms which distinguish between hormone and antihormone activated steroid receptors.
-
Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators.
-
Definition of the molecular basis for estrogen receptor-related receptor-alpha-cofactor interactions.
-
Definition of the molecular mechanism of action of tissue-selective oestrogen-receptor modulators.
-
Determination of estrogen receptor messenger ribonucleic acid (mRNA) and cytochrome P450 aromatase mRNA levels in adipocytes and adipose stromal cells by competitive polymerase chain reaction amplification.
-
Development of an ER action indicator mouse for the study of estrogens, selective ER modulators (SERMs), and Xenobiotics.
-
Development of peptide antagonists that target estrogen receptor beta-coactivator interactions.
-
Development of peptide antagonists that target estrogen receptor-cofactor interactions.
-
Differential biomarker gene and protein expressions in nonylphenol and estradiol-17beta treated juvenile rainbow trout (Oncorhynchus mykiss).
-
Differential cellular localization of CELSR2 and ING4 and correlations with hormone receptor status in breast cancer.
-
Differential interaction of the methoxychlor metabolite 2,2-bis-(p-hydroxyphenyl)-1,1,1-trichloroethane with estrogen receptors alpha and beta.
-
Differential molecular mechanism of the estrogen action that regulates lactoferrin gene in human and mouse.
-
Differential responsiveness of MCF-7 human breast cancer cell line stocks to the pineal hormone, melatonin.
-
Discovery and verification of protein differences between Er positive/Her2/neu negative breast tumor tissue and matched adjacent normal breast tissue.
-
Discovery of Tamoxifen and N-Desmethyl Tamoxifen Protein Targets in MCF-7 Cells Using Large-Scale Protein Folding and Stability Measurements.
-
Disruption of the mouse oestrogen receptor gene: resulting phenotypes and experimental findings.
-
Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors alpha and beta.
-
Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone.
-
Dynamic exchange at regulatory elements during chromatin remodeling underlies assisted loading mechanism.
-
Dynamic shuttling and intranuclear mobility of nuclear hormone receptors.
-
Dynamics of the epigenetic landscape during erythroid differentiation after GATA1 restoration.
-
ERRgamma regulates cardiac, gastric, and renal potassium homeostasis.
-
ERRα-Regulated Lactate Metabolism Contributes to Resistance to Targeted Therapies in Breast Cancer.
-
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).
-
EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor.
-
Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer.
-
Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.
-
Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases.
-
Effects of Pubertal Exposure to Dietary Soy on Estrogen Receptor Activity in the Breast of Cynomolgus Macaques.
-
Effects of castration and chronic steroid treatments on hypothalamic gonadotropin-releasing hormone content and pituitary gonadotropins in male wild-type and estrogen receptor-alpha knockout mice.
-
Effects of estrogen on very low density lipoproteins (VLDL) synthesis in avian liver slices in vitro: lack of correlation with nuclear estrogen receptors.
-
Effects of genistein or soy milk during late gestation and lactation on adult uterine organization in the rat.
-
Elucidation of the molecular mechanism of action of selective estrogen receptor modulators.
-
Embryonic expression and steroid regulation of brain aromatase cyp19a1b in zebrafish (Danio rerio).
-
Endocrine therapy in metastatic breast cancer.
-
Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance).
-
Endogenous protein kinase-C activation in osteoblast-like cells modulates responsiveness to estrogen and estrogen receptor levels.
-
Endometrial receptivities after leuprolide suppression and gonadotropin stimulation: histology, steroid receptor concentrations, and implantation rates.
-
Enhancement of estrogen receptor transcriptional activity by the coactivator GRIP-1 highlights the role of activation function 2 in determining estrogen receptor pharmacology.
-
Epigenetic Signatures Predict Pathologic Nodal Stage in Breast Cancer Patients with Estrogen Receptor-Positive, Clinically Node-Positive Disease.
-
Estrogen Receptor Signaling in the Immune System.
-
Estrogen and thyroid hormone interaction on regulation of gene expression.
-
Estrogen modulation of nuclear matrix-associated steroid hormone binding.
-
Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta.
-
Estrogen receptor alpha (ESR1) mutant A908G is not a common feature in benign and malignant proliferations of the breast.
-
Estrogen receptor determination by monoclonal antibody in fine needle aspiration breast cancer cytologies: a marker of hormone response.
-
Estrogen receptor determination in percutaneous bone marrow biopsies of patients with metastatic breast cancer.
-
Estrogen receptor gene disruption: molecular characterization and experimental and clinical phenotypes.
-
Estrogen receptor interconversion, factors regulating conformation and functions.
-
Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma.
-
Estrogen receptor transactivation in MCF-7 breast cancer cells by melatonin and growth factors.
-
Estrogen receptor-cofactor interactions as targets for novel drug discovery.
-
Estrogen receptor-β ligand treatment after disease onset is neuroprotective in the multiple sclerosis model.
-
Estrogen stimulates the transient association of calmodulin and myosin light chain kinase with the chicken liver nuclear matrix.
-
Estrogen up-regulates cyclooxygenase-2 via estrogen receptor in human uterine microvascular endothelial cells.
-
Estrogen-Related Receptor Alpha: An Under-Appreciated Potential Target for the Treatment of Metabolic Diseases.
-
Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
-
Estrogen-induced mitogenesis of MCF-7 cells does not require the induction of mitogen-activated protein kinase activity.
-
Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy.
-
Estrogen-related receptor alpha as a therapeutic target in cancer.
-
Estrogen-related receptor alpha induces the expression of vascular endothelial growth factor in breast cancer cells.
-
Estrogen-related receptor-α is a metabolic regulator of effector T-cell activation and differentiation.
-
Estrogen-related receptors stimulate pyruvate dehydrogenase kinase isoform 4 gene expression.
-
Estrogen/antiestrogen responsiveness in an in vivo/in vitro model for myometrial tumorigenesis.
-
Estrogenic activity of a dieldrin/toxaphene mixture in the mouse uterus, MCF-7 human breast cancer cells, and yeast-based estrogen receptor assays: no apparent synergism.
-
Estrogenic responses of larval sunshine bass (Morone saxatilis x M. Chrysops) exposed to New York City sewage effluent.
-
Estrogens and prostate cancer.
-
Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
-
Evaluation of a recombinant yeast cell estrogen screening assay.
-
Evaluation of chemicals with endocrine modulating activity in a yeast-based steroid hormone receptor gene transcription assay.
-
Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway.
-
Expression of functional estrogen receptor beta in locus coeruleus-derived Cath.a cells.
-
Expression of nuclear estrogen-binding sites within developing human fetal vagina and urogenital sinus.
-
Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
-
Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience.
-
Fasting-induced hepatic production of DHEA is regulated by PGC-1alpha, ERRalpha, and HNF4alpha.
-
Fertility treatment is associated with multiple meningiomas and younger age at diagnosis.
-
Fluoxymesterone stimulation of tumor marker secretion in patients with breast carcinoma.
-
Frequency of breast cancer subtypes among African American women in the AMBER consortium.
-
From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs).
-
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
-
Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
-
G protein-coupled estrogen receptor (GPER) expression in normal and abnormal endometrium.
-
G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
-
GPER1 is required to protect fetal health from maternal inflammation.
-
Gender differences in molecular remodeling in pressure overload hypertrophy.
-
Gene expression profiling for prediction of clinical characteristics of breast cancer.
-
Gene expression profiling of breast cancer in relation to estrogen receptor status and estrogen-metabolizing enzymes: clinical implications.
-
Genetic polymorphisms of selected DNA repair genes, estrogen and progesterone receptor status, and breast cancer risk.
-
Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence.
-
Genomic structure and embryonic expression of estrogen receptor beta a (ERbetaa) in zebrafish (Danio rerio).
-
High level expression of biologically active estrogen receptor in Saccharomyces cerevisiae.
-
Higher risk tumor features are not associated with higher nodal stage in patients with estrogen receptor-positive, node-positive breast cancer.
-
Hormonal and personal effects on estrogen receptors in breast cancer.
-
Hormone therapy: physiological complexity belies therapeutic simplicity.
-
Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status.
-
Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program.
-
Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions.
-
Identification and characterization of novel estrogen receptor-beta-sparing antiprogestins.
-
Identification and structure-activity relationship of phenolic acyl hydrazones as selective agonists for the estrogen-related orphan nuclear receptors ERRbeta and ERRgamma.
-
Identification of a negative regulatory function for steroid receptors.
-
Identification of a negative regulatory surface within estrogen receptor alpha provides evidence in support of a role for corepressors in regulating cellular responses to agonists and antagonists.
-
Identification of a new subclass of Alu DNA repeats which can function as estrogen receptor-dependent transcriptional enhancers.
-
Identification of a robust gene signature that predicts breast cancer outcome in independent data sets.
-
Identification of a third autonomous activation domain within the human estrogen receptor.
-
Identification of an enhancer element in the estrogen receptor upstream region: implications for regulation of ER transcription in breast cancer.
-
Identification of novel steroid-response elements.
-
Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study.
-
Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity.
-
Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods.
-
Immunohistochemical expression of TAG-72 in normal and malignant endometrium: correlation of antigen expression with estrogen receptor and progesterone receptor levels.
-
Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study.
-
In situ distinction between steroid receptor binding and transactivation at a target gene.
-
In vivo modulation of 17 beta-estradiol-induced vitellogenin synthesis and estrogen receptor in rainbow trout (Oncorhynchus mykiss) liver cells by beta-naphthoflavone.
-
Increased expression of estrogen receptor beta in pachytene spermatocytes after short-term methoxyacetic acid administration.
-
Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells.
-
Inherited variants in mitochondrial biogenesis genes may influence epithelial ovarian cancer risk.
-
Inhibition of ERRα Prevents Mitochondrial Pyruvate Uptake Exposing NADPH-Generating Pathways as Targetable Vulnerabilities in Breast Cancer.
-
Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma.
-
Interaction of estrogen receptor alpha with protein kinase C alpha and c-Src in osteoblasts during differentiation.
-
Interaction of methoxychlor and related compounds with estrogen receptor alpha and beta, and androgen receptor: structure-activity studies.
-
Interactions of estrogen- and thyroid hormone receptors on a progesterone receptor estrogen response element (ERE) sequence: a comparison with the vitellogenin A2 consensus ERE.
-
Interlaboratory variation in results from immunohistochemical assessment of estrogen receptor status.
-
Intra-tumor molecular heterogeneity in breast cancer: definitions of measures and association with distant recurrence-free survival.
-
Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome.
-
Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification.
-
Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study.
-
Investigation of antiestrogenic properties of unleaded gasoline in female mice.
-
Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression.
-
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
-
Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
-
Lactoferrin gene expression is estrogen responsive in human and rhesus monkey endometrium.
-
Laser scanning cytometry quantification of estrogen receptors in breast cancer.
-
Ligand-dependent and -independent function of the transactivation regions of the human estrogen receptor in yeast.
-
Ligand-selective interactions of ER detected in living cells by fluorescence resonance energy transfer.
-
Long-term prognostic implications of sex-steroid receptors in human cancer.
-
Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study.
-
Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.
-
Magnetic separation to concentrate the estrogen receptor from adipose tissue for western analysis.
-
Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.
-
Malignant effusions in recurrent breast cancer: steroid hormone receptor analysis of effusion fluid derived cells.
-
Malignant transformation of the human endometrium is associated with overexpression of lactoferrin messenger RNA and protein.
-
Mapping and characterization of the functional domains responsible for the differential activity of the A and B isoforms of the human progesterone receptor.
-
Mechanism-based discovery as an approach to identify the next generation of estrogen receptor modulators.
-
Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells.
-
Mesothelin, a novel immunotherapy target for triple negative breast cancer.
-
Mining the complexities of the estrogen signaling pathways for novel therapeutics.
-
Modulation of estrogen receptor levels in mouse uterus by protein kinase C isoenzymes.
-
Modulation of estrogen receptor-alpha transcriptional activity by the coactivator PGC-1.
-
Modulation of murine breast tumor vascularity, hypoxia and chemotherapeutic response by exercise.
-
Molecular cloning of rainbow trout (Oncorhynchus mykiss) eggshell zona radiata protein complementary DNA: mRNA expression in 17beta-estradiol- and nonylphenol-treated fish.
-
Molecular mechanics simulation of the interaction of estrogen receptor with estrogen regulatory element.
-
Molecular pathways: the metabolic regulator estrogen-related receptor α as a therapeutic target in cancer.
-
Mouse retinal pigmented epithelial cell lines retain their phenotypic characteristics after transfection with human papilloma virus: a new tool to further the study of RPE biology.
-
Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer.
-
Mutational analysis of the estrogen-receptor gene in endometrial carcinoma.
-
Neoadjuvant Systemic Therapy for Breast Cancer: Factors Influencing Surgeons' Referrals.
-
Neuroendocrine gene polymorphisms and susceptibility to juvenile idiopathic arthritis.
-
Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer.
-
Non-steroidal anti-inflammatory drug use, hormone receptor status, and breast cancer-specific mortality in the Carolina Breast Cancer Study.
-
Novel Hormone Receptors Present in Apocrine Cystadenoma of the Eyelid.
-
Novel Transcriptional Mechanisms for Regulating Metabolism by Thyroid Hormone.
-
Novel estrogen response elements identified by genetic selection in yeast are differentially responsive to estrogens and antiestrogens in mammalian cells.
-
Novel prognostic markers for patients with triple-negative breast cancer.
-
Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care.
-
Nuclear estrogen receptor in the avian liver: correlation with biologic response.
-
Obesity and body fat distribution and breast cancer prognosis.
-
Oestrogen receptors enhance dopamine neurone survival in rat midbrain.
-
On the intractability of estrogen-related receptor alpha as a target for activation by small molecules.
-
Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ.
-
Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features.
-
PGC-1alpha regulates a HIF2alpha-dependent switch in skeletal muscle fiber types.
-
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
-
Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India.
-
Paradoxical relationship between chromosomal instability and survival outcome in cancer.
-
Pathobiologic Stratification of Oncotype DX Recurrence Scores and Comparative Validation of 3 Surrogate Models.
-
Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.
-
Pathology and pathophysiology of uterine smooth-muscle tumors.
-
Patterns of de-novo metastasis and breast cancer-specific mortality by race and molecular subtype in the SEER population-based dataset.
-
Peptide antagonists of the human estrogen receptor.
-
Performance of preoperative breast MRI based on breast cancer molecular subtype.
-
Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.
-
Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance).
-
Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.
-
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.
-
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.
-
Poor Endometrial Proliferation After Clomiphene is Associated With Altered Estrogen Action.
-
Population and target considerations for triple-negative breast cancer clinical trials.
-
Potency of combined estrogenic pesticides.
-
Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2- Breast Cancer.
-
Predicting the clinical status of human breast cancer by using gene expression profiles.
-
Prevention of the polycystic ovarian phenotype and characterization of ovulatory capacity in the estrogen receptor-alpha knockout mouse.
-
Problems for risk assessment of endocrine-active estrogenic compounds.
-
Progesterone Signaling in Endometrial Epithelial Organoids.
-
Progesterone receptor activity in leiomyomatosis peritonealis disseminata.
-
Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013.
-
Prognostic factors for fibromatoses: a correlation of proliferation index, estrogen receptor, p53, retinoblastoma, and src gene products and clinical features with outcome.
-
Prognostic index score and clinical prediction model of local regional recurrence after mastectomy in breast cancer patients.
-
Prostaglandin-mediated effects in early canine corpus luteum: In vivo effects on vascular and immune factors.
-
Prostatic mucinous adenocarcinoma. A Cowper gland carcinoma mimicker.
-
Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression.
-
Protein kinase C modulates estrogen receptors in differentiated osteoblastic cells in vitro.
-
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
-
Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study.
-
Racial disparities in individual breast cancer outcomes by hormone-receptor subtype, area-level socio-economic status and healthcare resources.
-
Randomized comparison of tamoxifen versus diethylstilbestrol in estrogen receptor-positive or -unknown metastatic breast cancer: a Southeastern Cancer Study Group trial.
-
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.
-
Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer.
-
Real-world Evidence of Diagnostic Testing and Treatment Patterns in US Patients With Breast Cancer With Implications for Treatment Biomarkers From RNA Sequencing Data.
-
Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study.
-
Receptor interconversion model of hormone action. 2. Requirement of both kinase and phosphatase activities for conferring estrogen binding activity to the estrogen receptor.
-
Receptor-selective coactivators as tools to define the biology of specific receptor-coactivator pairs.
-
Regulation of aryl hydrocarbon receptor function by selective estrogen receptor modulators.
-
Regulation of estrogen receptors and MMP-2 expression by estrogens in human retinal pigment epithelium.
-
Relationship between adipose stromal-vascular cells and adipocytes in human adipose tissue.
-
Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones.
-
Relationship of age and menopausal status to estrogen receptor content in primary carcinoma of the breast.
-
Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer.
-
Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study.
-
Research resource: Transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexes.
-
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
-
Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger.
-
Risk factors for estrogen receptor-positive breast cancer.
-
Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history.
-
Risk of positive nonsentinel nodes in women with 1-2 positive sentinel nodes related to age and molecular subtype approximated by receptor status.
-
Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines.
-
Role of estrogen receptor signaling required for endometriosis-like lesion establishment in a mouse model.
-
S-nitrosylation of Ras in breast cancer.
-
Selective estrogen receptor modulators (SERMs): A first step in the development of perfect hormone replacement therapy regimen.
-
Sex steroid receptor analysis in human melanoma.
-
Sex steroid receptor concentration in breast carcinoma tissue: effect of devascularization during mastectomy.
-
Smoothing spline-based score tests for proportional hazards models.
-
Specific Histopathologic Features Aid in Distinguishing Diffuse-type Gastric Adenocarcinoma From Metastatic Lobular Breast Carcinoma.
-
Steroid hormone receptors selectively affect transcriptional activation but not basal repression by thyroid hormone receptors.
-
Structural organization and regulation of the chicken estrogen receptor.
-
Structural requirements for high affinity ligand binding by estrogen receptors: a comparative analysis of truncated and full length estrogen receptors expressed in bacteria, yeast, and mammalian cells.
-
Structure-guided synthesis of tamoxifen analogs with improved selectivity for the orphan ERRgamma.
-
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.
-
Taking a Second Look at Neoadjuvant Endocrine Therapy for the Treatment of Early Stage Estrogen Receptor Positive Breast Cancer During the COVID-19 Outbreak.
-
Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
-
Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models.
-
Targeted disruption of the estrogen receptor-alpha gene in female mice: characterization of ovarian responses and phenotype in the adult.
-
Targeting mutant estrogen receptors.
-
Temporal control of gene deletion in sensory ganglia using a tamoxifen-inducible Advillin-Cre-ERT2 recombinase mouse.
-
Temporally distinct and ligand-specific recruitment of nuclear receptor-interacting peptides and cofactors to subnuclear domains containing the estrogen receptor.
-
The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells.
-
The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene.
-
The Association of Extent of Axillary Surgery and Survival in Women with N2-3 Invasive Breast Cancer.
-
The G Protein-Coupled Estrogen Receptor Agonist G-1 Inhibits Nuclear Estrogen Receptor Activity and Stimulates Novel Phosphoproteomic Signatures.
-
The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells.
-
The association between progesterone receptor expression and survival in women with adult granulosa cell tumors.
-
The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers.
-
The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer.
-
The effects of NSAIDs on breast cancer prognostic factors.
-
The estrogen receptor as a mediator of the pathological actions of cholesterol in breast cancer.
-
The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens.
-
The granulin-epithelin precursor is a steroid-regulated growth factor in endometrial cancer.
-
The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators.
-
The metabolic co-regulator PGC1α suppresses prostate cancer metastasis.
-
The metabolic regulator ERRα, a downstream target of HER2/IGF-1R, as a therapeutic target in breast cancer.
-
The molecular determinants of estrogen receptor pharmacology.
-
The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.
-
The molecular pharmacology of estrogen receptor modulators: implications for the treatment of breast cancer.
-
The molecular pharmacology of ovarian steroid receptors.
-
The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury?
-
The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features.
-
The oxysterol, 27-hydroxycholesterol, links cholesterol metabolism to bone homeostasis through its actions on the estrogen and liver X receptors.
-
Thyroid hormone receptor and ERRα coordinately regulate mitochondrial fission, mitophagy, biogenesis, and function.
-
Toxicology of environmental estrogens.
-
Transactivation functions facilitate the disruption of chromatin structure by estrogen receptor derivatives in vivo.
-
Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ.
-
Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer.
-
Type and duration of exogenous hormone use affects breast cancer histology.
-
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
-
Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors.
-
Validating a prognostic scoring system for postmastectomy locoregional recurrence in breast cancer.
-
Validation of a breast cancer risk prediction model developed for Black women.
-
WNT11 expression is induced by estrogen-related receptor alpha and beta-catenin and acts in an autocrine manner to increase cancer cell migration.
-
What threshold for adjuvant therapy in older breast cancer patients?
-
Whole-genome analysis informs breast cancer response to aromatase inhibition.
-
[Treatment of primary cancer of the breast in elderly women. Role of hormone therapy].
-
p53 does not repress hypoxia-induced transcription of the vascular endothelial growth factor gene.
-
Keywords of People
-
-
Berchuck, Andrew,
James M. Ingram Distinguished Professor of Gynecologic Oncology,
Obstetrics and Gynecology, Gynecologic Oncology
-
McDonnell, Donald Patrick,
Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine,
Cell Biology
-
Moorman, Patricia Gripka,
Professor Emeritus in Family Medicine and Community Health,
Duke Cancer Institute
-
Shinohara, Mari L.,
Associate Professor of Immunology,
Cell Biology